Polaris Wealth Advisory Group LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 4,404.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 105,439 shares of the company’s stock after buying an additional 103,098 shares during the period. Johnson & Johnson comprises 1.4% of Polaris Wealth Advisory Group LLC’s investment portfolio, making the stock its 23rd biggest holding. Polaris Wealth Advisory Group LLC’s holdings in Johnson & Johnson were worth $18,439,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Johnson & Johnson by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after acquiring an additional 2,815,655 shares during the period. State Street Corp grew its holdings in shares of Johnson & Johnson by 0.6% in the 3rd quarter. State Street Corp now owns 141,886,311 shares of the company’s stock worth $23,178,548,000 after acquiring an additional 803,013 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Johnson & Johnson by 3.3% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock worth $4,154,022,000 after acquiring an additional 805,831 shares during the period. Legal & General Group Plc grew its holdings in Johnson & Johnson by 2.3% during the 2nd quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after buying an additional 421,779 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Johnson & Johnson by 1.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after buying an additional 328,297 shares during the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Trading Up 1.0 %
Shares of JNJ opened at $153.31 on Thursday. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $399.26 billion, a P/E ratio of 22.75, a price-to-earnings-growth ratio of 2.63 and a beta of 0.54. The stock’s fifty day simple moving average is $158.62 and its 200 day simple moving average is $167.29. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $186.69.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were given a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.95%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 67.06%.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.35% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
A number of brokerages have commented on JNJ. Guggenheim began coverage on Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. Morgan Stanley increased their target price on Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a report on Wednesday, January 25th. UBS Group began coverage on Johnson & Johnson in a report on Tuesday. They set a “neutral” rating and a $164.00 target price on the stock. Finally, SVB Leerink lowered their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $173.67.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Dave & Buster’s Rebound Could Score for Investors
- Cal-Maine: Is it Time to Chase this Stock Higher?
- The Most Important Warren Buffett Stock for Investors: His Own
- Three Mid Caps Wall Street Sees Doubling Within 12 Months
- It’s No Stretch: Lululemon Could Break Out of its Range
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
